Search results
Author(s):
David Morrow
Added:
4 years ago
In this video, Prof David A Morrow, Professor of Medicine and Cardiology from the Harvard Medical School, Boston, MA, US, discusses the emerging data on utilising Angiotensin Receptor-Neprilysin Inhibitor (ARNI) therapy in complex patients.
Filmed on site at ESC 2019 by Radcliffe Cardiology.
This interview is a component of a wider Radcliffe Education programme entitled,'Review of emerging…
View more
Author(s):
Sam Hayman
,
John J Atherton
Added:
3 years ago
Heart failure (HF) is associated with significant morbidity and mortality and confers a major economic burden.1 Large randomised controlled trials (RCTs) have demonstrated that inhibition of the renin–angiotensin– aldosterone and sympathetic nervous systems improve outcomes in patients with HF and a reduced left ventricular ejection fraction (HFrEF) (see Figure 1),2–9 with clinical guidelines…
View more
Author(s):
Juan Tamargo
Added:
3 years ago
Chronic heart failure (HF) is a complex and progressive clinical syndrome resulting from any abnormality of cardiac structure or function. The American College of Cardiology Foundation/American Heart Association guideline defines HF as ‘a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood’.1 The European Society of…
View more
Neprilysin as a Biomarker
Author(s):
Noemi Pavo
,
Suriya Prausmüller
,
Philipp E Bartko
,
et al
Added:
3 years ago
Article
Author(s):
Michelle Kittleson
Added:
2 years ago
In this video, Dr Michelle Kittleson (Cedars-Sinai California Heart Center, Los Angeles, CA, US) provides her expert opinion on the 2022 ACC guidelines for the management of Heart Failure. Dr Kittleson outlines the applicability of these recommendations, as well as the barriers and opportunities.
Recorded remotely from Beverley-Hills, 2022.
Interviewer: Mirjam Boros
View more
Author(s):
John JV McMurray
Added:
1 year ago
ESC Congress – Prof John McMurray (University of Glasgow, UK) joined us to discuss the finding of the PERSPECTIVE trial (NCT02884206).
The trial assessed whether the angiotensin receptor-neprilysin inhibitor (ARNi), sacubitril/valsartan (Novartis) has any negative impact on cognitive function in people who have heart failure with preserved ejection fraction (HFpEF) when compared with HFpEF…
View more
Author(s):
Mauro Gori
,
James L Januzzi
,
Emilia D’Elia
,
et al
Added:
3 years ago
Author(s):
Thomas G von Lueder
,
Dipak Kotecha
,
Dan Atar
,
et al
Added:
3 years ago
Heart Failure (HF) constitutes a major global health problem, evidenced by substantial morbidity and mortality, requiring enormous healthcare-related expenditure. HF is associated with high symptomatic burden, and with a relentless and progressive clinical course towards end-stage disease. A large body of epidemiological data suggests that the prognosis in HF is as poor as in advanced cancer.1…
View more
Author(s):
Lampros Papadimitriou
,
Charles K Moore
,
Javed Butler
,
et al
Added:
4 years ago
Heart failure (HF) is a global epidemic which affects about 6 million adults in the US. It is projected that by 2030 the total cost of HF will reach US$70 billion. Despite the development of novel drugs and devices, the mortality burden of HF remains high, with one in three patients dying within 1 year of hospitalisation for HF and 40–50% within 5 years of diagnosis.1
Patients with HF are…
View more
Foreword
Author(s):
Andrew JS Coats
,
Giuseppe Rosano
Added:
3 years ago
Article